Search Results - "Oudard, Stéphane"

Progress in emerging therapies for advanced prostate cancer by Oudard, Stéphane

“…Abstract The landscape of prostate cancer treatment is rapidly changing as extensive research into potential therapies yields new options. In this article, the…”
Get full text

Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology by Droz, Jean-Pierre, Albrand, Gilles, Gillessen, Silke, Hughes, Simon, Mottet, Nicolas, Oudard, Stéphane, Payne, Heather, Puts, Martine, Zulian, Gilbert, Balducci, Lodovico, Aapro, Matti

“…Abstract Context Prostate cancer is the most frequent male cancer. Since the median age of diagnosis is 66 yr, many patients require both geriatric and…”
Get full text

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial by Gravis, Gwenaelle, Boher, Jean-Marie, Joly, Florence, Soulié, Michel, Albiges, Laurence, Priou, Franck, Latorzeff, Igor, Delva, Remy, Krakowski, Ivan, Laguerre, Brigitte, Rolland, Frédéric, Théodore, Christine, Deplanque, Gael, Ferrero, Jean-Marc, Culine, Stéphane, Mourey, Loïc, Beuzeboc, Philippe, Habibian, Muriel, Oudard, Stéphane, Fizazi, Karim

“…Abstract Background The role of chemotherapy in metastatic non castrate prostate cancer (mNCPC) is debated. Survival benefits of docetaxel (D) added to…”
Get full text

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial by Powles, Thomas, Durán, Ignacio, van der Heijden, Michiel S, Loriot, Yohann, Vogelzang, Nicholas J, De Giorgi, Ugo, Oudard, Stéphane, Retz, Margitta M, Castellano, Daniel, Bamias, Aristotelis, Fléchon, Aude, Gravis, Gwenaëlle, Hussain, Syed, Takano, Toshimi, Leng, Ning, Kadel, Edward E, Banchereau, Romain, Hegde, Priti S, Mariathasan, Sanjeev, Cui, Na, Shen, Xiaodong, Derleth, Christina L, Green, Marjorie C, Ravaud, Alain

“…Few options exist for patients with locally advanced or metastatic urothelial carcinoma after progression with platinum-based chemotherapy. We aimed to assess…”
Get full text

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial by Gore, Martin E, Prof, Szczylik, Cezary, Prof, Porta, Camillo, MD, Bracarda, Sergio, Prof, Bjarnason, Georg A, MD, Oudard, Stéphane, Prof, Hariharan, Subramanian, MD, Lee, Se-Hoon, MD, Haanen, John, Prof, Castellano, Daniel, MD, Vrdoljak, Eduard, MD, Schöffski, Patrick, Prof, Mainwaring, Paul, Prof, Nieto, Alejandra, MD, Yuan, Jinyu, PhD, Bukowski, Ronald, Prof

“…Summary Background Results from clinical trials have established sunitinib as a standard of care for first-line treatment of advanced or metastatic renal-cell…”
Get full text

MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights by Simonaggio, Audrey, Ambrosetti, Damien, Verkarre, Virginie, Auvray, Marie, Oudard, Stéphane, Vano, Yann-Alexandre

“…MiTF/TFE translocation renal cell carcinoma (tRCC) is a rare and aggressive subtype of RCC representing the most prevalent RCC in the pediatric population (up…”
Get full text

Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients by Vano, Yann-Alexandre, Oudard, Stéphane, By, Marie-Agnès, Têtu, Pauline, Thibault, Constance, Aboudagga, Hail, Scotté, Florian, Elaidi, Reza

“…This study assessed the prognostic value of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic solid tumors. Clinical and…”
Get full text

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA by Oudard, Stéphane, Fizazi, Karim, Sengeløv, Lisa, Daugaard, Gedske, Saad, Fred, Hansen, Steinbjørn, Hjälm-Eriksson, Marie, Jassem, Jacek, Thiery-Vuillemin, Antoine, Caffo, Orazio, Castellano, Daniel, Mainwaring, Paul N, Bernard, John, Shen, Liji, Chadjaa, Mustapha, Sartor, Oliver

“…Purpose In patients with metastatic castration-resistant prostate cancer (mCRPC), overall survival (OS) is significantly improved with cabazitaxel versus…”
Get full text

Apalutamide and Overall Survival in Prostate Cancer by Smith, Matthew R., Saad, Fred, Chowdhury, Simon, Oudard, Stéphane, Hadaschik, Boris A., Graff, Julie N., Olmos, David, Mainwaring, Paul N., Lee, Ji Youl, Uemura, Hiroji, De Porre, Peter, Smith, Andressa A., Brookman-May, Sabine D., Li, Susan, Zhang, Ke, Rooney, Brendan, Lopez-Gitlitz, Angela, Small, Eric J.

“…The phase 3 SPARTAN study evaluated apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and…”
Get full text

Home Blood-Pressure Monitoring in Patients Receiving Sunitinib by Azizi, Michel, Chedid, Antoine, Oudard, Stéphane

“…To the Editor: The use of sunitinib, an inhibitor of the split-kinase-domain family of receptor tyrosine kinases (including vascular endothelial growth factor…”
Get full text

Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities by Cohen, Roger B., Oudard, Stéphane

“…Summary Treatment of metastatic renal cell carcinoma (mRCC) has evolved rapidly over the last two decades as major pathways involved in pathogenesis have been…”
Get full text

Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review by Sun, Maxine, Shariat, Shahrokh F, Cheng, Christopher, Ficarra, Vincenzo, Murai, Masaru, Oudard, Stéphane, Pantuck, Allan J, Zigeuner, Richard, Karakiewicz, Pierre I

“…Abstract Context The natural history of renal cell carcinoma (RCC) is highly unpredictable. Small renal masses may be accompanied by metastatic disease…”
Get full text

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial by Motzer, Robert J, Dr, Prof, Escudier, Bernard, MD, Oudard, Stéphane, Prof, Hutson, Thomas E, Prof, Porta, Camillo, MD, Bracarda, Sergio, MD, Grünwald, Viktor, Prof, Thompson, John A, Prof, Figlin, Robert A, Prof, Hollaender, Norbert, PhD, Urbanowitz, Gladys, BS, Berg, William J, MD, Kay, Andrea, MD, Lebwohl, David, MD, Ravaud, Alain, Prof

“…Summary Background Everolimus (RAD001) is an orally administered inhibitor of the mammalian target of rapamycin (mTOR), a therapeutic target for metastatic…”
Get full text

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial by ESCUDIER, Bernard, EISEN, Tim, DEMKOW, Tomasz, HUTSON, Thomas E, GORE, Martin, ANDERSON, Sibyl, HOFILENA, Gloria, MINGHUA SHAN, PENA, Carol, LATHIA, Chetan, BUKOWSKI, Ronald M, STADLER, Walter M, SZCZYLIK, Cezary, OUDARD, Stéphane, STAEHLER, Michael, NEGRIER, Sylvie, CHEVREAU, Christine, DESAI, Apurva A, ROLLAND, Frédéric

“…Mature survival data and evaluation of vascular endothelial growth factor (VEGF) as a prognostic biomarker from the Treatment Approaches in Renal Cancer Global…”
Get full text

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma by MOTZER, Robert J, HUTSON, Thomas E, GARCIA-DEL-MURO, Xavier, SOSMAN, Jeffrey A, SOLSKA, Ewa, WILDING, George, THOMPSON, John A, KIM, Sindy T, CHEN, Isan, XIN HUANG, FIGLIN, Robert A, TOMCZAK, Piotr, MICHAELSON, M. Dror, BUKOWSKI, Ronald M, OUDARD, Stéphane, NEGRIER, Sylvie, SZCZYLIK, Cezary, PILI, Roberto, BJARNASON, Georg A

“…A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free survival (primary end point) as…”
Get full text

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial by Motzer, Robert J., Escudier, Bernard, George, Saby, Hammers, Hans J., Srinivas, Sandhya, Tykodi, Scott S., Sosman, Jeffrey A., Plimack, Elizabeth R., Procopio, Giuseppe, McDermott, David F., Castellano, Daniel, Choueiri, Toni K., Donskov, Frede, Gurney, Howard, Oudard, Stéphane, Richardet, Martin, Peltola, Katriina, Alva, Ajjai S., Carducci, Michael, Wagstaff, John, Chevreau, Christine, Fukasawa, Satoshi, Tomita, Yoshihiko, Gauler, Thomas C., Kollmannsberger, Christian K., Schutz, Fabio A., Larkin, James, Cella, David, McHenry, M. Brent, Saggi, Shruti Shally, Tannir, Nizar M.

“…Background CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved…”
Get full text

Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma by Pourmir, Ivan, Noel, Johanna, Simonaggio, Audrey, Oudard, Stéphane, Vano, Yann-Alexandre

“…In the last few years, the standard of care for metastatic clear cell renal cell carcinoma (mccRCC) has changed dramatically with the emergence of the immune…”
Get full text

Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting by Beuselinck, Benoit, Job, Sylvie, Becht, Etienne, Karadimou, Alexandra, Verkarre, Virginie, Couchy, Gabrielle, Giraldo, Nicolas, Rioux-Leclercq, Nathalie, Molinié, Vincent, Sibony, Mathilde, Elaidi, Reza, Teghom, Corinne, Patard, Jean-Jacques, Méjean, Arnaud, Fridman, Wolf Herman, Sautès-Fridman, Catherine, de Reyniès, Aurélien, Oudard, Stéphane, Zucman-Rossi, Jessica

“…Selecting patients with metastatic clear-cell renal cell carcinoma (m-ccRCC) who might benefit from treatment with targeted tyrosine kinase inhibitors (TKI) is…”
Get full text

Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) by Simonaggio, Audrey, Epaillard, Nicolas, Pobel, Cédric, Moreira, Marco, Oudard, Stéphane, Vano, Yann-Alexandre

“…Renal cell carcinoma (RCC) is the seventh most frequently diagnosed malignancy with an increasing incidence in developed countries. Despite a greater…”
Get full text

Docetaxel: time to reassess combination strategies by Oudard, Stéphane

Get full text